Promore Pharma AB entered into voluntary liquidation in accordance with a decision made at a general meeting on October 5, 2023. In the spring, the company received the final results of the PHSU05 clinical trial, which showed that the treatment effect of ensereptide was insufficient to justify further investments, which is why the board later decided to discontinue this development project. This resulted in a sharp decline in the company’s market capitalization. In addition, financial m...